Join
Live feed
·
PRReleasevia Quantisnow
Ocugen Inc. logo

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

ByQuantisnow·Wall Street's wire, on your screen.
OCGN· Ocugen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCGN (Ocugen Inc.) and more on Quantisnow.